Tempus AI (TEM) is rated Strong Buy with a 12-month price target of $71, indicating a 67% potential gain despite a recent 60% decline in its share price. The company's strength lies in its integrated genomic and clinical data platform, which creates a competitive moat, further supported by its acquisition of Ambry Genetics and growing partnerships with pharmaceutical companies. Diagnostics revenue has more than doubled year-over-year, and high-margin data and applications segments are improving overall margins. With a record $1.1 billion total contract value and a transition towards positive adjusted EBITDA, Tempus AI is positioned for a potential re-rating as a high-growth healthcare AI platform.
